BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2006

View Archived Issues

Weekly DN-101 administration assessed in cancer patients

Read More

In vitro studies reveal effects of pirfenidone alone and with IFN-gamma-1B

Read More

Lestaurtinib, midostaurin cytotoxic in acute myeloid leukemia blasts

Read More

Novel anti-HLA-DR antibody may potentiate rituximab's antilymphoma activity

Read More

P. falciparum methionine aminopeptidase 1: novel target for antimalarial drugs

Read More

Small MRP1 inhibitor sensitizes resistant neuroblastoma tumors to chemotherapy

Read More

ADC-4022 for COPD and asthma enters clinic

Read More

Rivaroxaban phase III program outlined in stroke prevention and VTE

Read More

KB-002 studied in rheumatoid arthritis patients

Read More

ACR-325 enters clinic for treatment of psychosis

Read More

3M to sell global branded pharmaceuticals business

Read More

MedImmune files IND for cell culture-based influenza vaccine

Read More

MedImmune to sell CytoGam to ZLB Behring

Read More

Pozen submits full response to Trexima approvable letter

Read More

Phase IIb study evaluates AN-0128 in children with atopic dermatitis

Read More

Cardiovascular outcomes study not required for naproxcinod

Read More

UCB publishes offer document for takeover of Schwarz Pharma

Read More

IND filing for CollaRx Gentamicin in diabetic foot ulcers

Read More

GlycoPEG-GCSF studied in phase I trial

Read More

ARQ-501 demonstrates tolerability and signs of antitumor activity

Read More

Neurobiological Technologies makes case for Viprinex in stroke

Read More

Prochymal shows good complete response rate in GVHD

Read More

Recent patents describe novel antidiabetic agents

Read More

Novel cannabinoid CB1 receptor antagonists emerge from Pfizer R&D

Read More

Recent patents describe new compounds for thrombotic disorders

Read More

SLV-308 shows potential for concomitant treatment of parkinsonian symptoms

Read More

Lacosamide could be useful in essential tremor, dyskinetic side effects secondary to antipsychotics

Read More

AMPA receptor antagonist E-2007 shows positive effects as adjunct therapy to levodopa

Read More

Genentech to acquire Tanox

Read More

Mexican approval for Acomplia

Read More

Mirapex approved for restless legs syndrome

Read More

Presurgical bevacizumab/erlotinib safe and effective in RCC

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing